Metformin enhances radiosensitivity in hepatocellular carcinoma by inhibition of specificity protein 1 and epithelial-to-mesenchymal transition

Zhang, Kefen; Wang, Jun; Guo, Jiao; Huang, Yi; Huang, Tianren

doi:10.4103/jcrt.jcrt_297_19

Cited by 7 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following title and abstract screening, there were 154 studies deemed eligible for full-text assessment. Eleven studies were ultimately included in the systematic review [ 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 ]. One study included both pre-clinical and clinical data and was thus considered two separate studies [ 89 ].…”

Section: Resultsmentioning

confidence: 99%

“…Both pre-clinical and clinical studies were identified through the literature search process. Of the 11 total studies included in this systematic review, 5 studies were classified as human preclinical studies [ 87 , 88 , 89 , 90 , 91 ] and 6 studies were classified as human clinical studies [ 82 , 83 , 84 , 85 , 86 , 89 ]. All included studies were full-text publications and were published between 2012 and 2022.…”

Section: Resultsmentioning

confidence: 99%

“…Among the 11 studies, 2 studies performed radiofrequency ablation (RFA) [ 82 , 90 ], 3 studies performed transarterial chemoembolization (TACE) [ 83 , 86 , 89 ], and 1 study performed Y90 radioembolization (Y90 RS) [ 84 ]. Four of the eleven studies performed external beam radiation therapies, which included stereotactic body radiotherapy (SBRT)/hypofractionated radiotherapy (HypoRT) (one study) [ 85 ], gamma-ray radiation/neutron radiation (two studies) [ 87 , 91 ], and ionizing radiation (one study) [ 88 ]. There was a total of 805 patients among the six clinical studies, with males representing 50.6% of total patients.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions

Choksi,

Elsayed,

Kokabi

2023

Cancers

View full text Add to dashboard Cite

This article aimed to examine the effect of metformin use on improving outcomes after liver-directed therapy in patients with HCC and identify future directions with the adjuvant use of and potential therapeutic agents that operate on similar mechanistic pathways. Databases were queried to identify pertinent articles on metformin’s use as an anti-cancer agent in HCC. Eleven studies were included, with five pre-clinical and six clinical studies. The mean overall survival (OS) and progression-free survival were both higher in the locoregional therapy (LRT) + metformin-treated groups. The outcome variables, including local tumor recurrence rate, reduction in HCC tumor growth and size, tumor growth, proliferation, migration and invasion of HCC cells, HCC cell apoptosis, DNA damage, and cell cycle arrest, showed favorable outcomes in the LRT + metformin-treated groups compared with LRT alone. This systemic review provides a strong signal that metformin use can improve the tumor response after locoregional therapy. Well-controlled prospective trials will be needed to elucidate the potential antitumor effects of metformin and other mTOR inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions

Choksi,

Elsayed,

Kokabi

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Metformin is a biguanide used for the treatment of type II diabetes. Previously, it has been report that metformin can exert radiosensitivity and radioprotective effects, and it can enhance the radiation response by reducing tumor stem cells, and suppressing proliferation and hypoxia (79)(80)(81)(82). Additionally, metformin may prevent IR-induced esophageal carcinoma invasion and metastasis (83).…”

Section: Carbamazepine (Cbz)mentioning

confidence: 99%

Radioprotective countermeasures for radiation injury (Review)

Liu

Liang

et al. 2023

Mol Med Rep

View full text Add to dashboard Cite

A series of physiological and pathological changes occur after radiotherapy and accidental exposure to ionizing radiation (IR). These changes cause serious damage to human tissues and can lead to death. Radioprotective countermeasures are radioprotective agents that prevent and reduce IR injury or have therapeutic effects. Based on a good understanding of radiobiology, a number of protective agents have achieved positive results in early clinical trials. The present review grouped known radioprotective agents according to biochemical categories and potential clinical use, and reviewed radiation countermeasures, i.e., radioprotectors, radiation mitigators and radiotherapeutic agents, with an emphasis on their current status and research progress. The aim of the present review is to facilitate the selection and application of suitable radioprotectors for clinicians and researchers, to prevent or reduce IR injury.

show abstract

“…Focusing on the role of metformin in radiation therapy, many clinical trials suggest an influence on tumor response and an increase in survival rate [ 97 ]. In many cancers, metformin preferentially interacts with cancer stem cells by potentiating the genotoxic effect of radiation [ 56 , 98 ].…”

Section: Conventional Medicaments As Radiosensitizers In Off-label Usementioning

confidence: 99%

A Cross-Talk about Radioresistance in Lung Cancer—How to Improve Radiosensitivity According to Chinese Medicine and Medicaments That Commonly Occur in Pharmacies

Nowak

Bil‐Lula

Śliwińska-Mossoń

2023

IJMS

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers in the population and is characterized by non-specific symptoms that delay the diagnosis and reduce the effectiveness of oncological treatment. Due to the difficult placement of the tumor, one of the main methods of lung cancer treatment is radiotherapy, which damages the DNA of cancer cells, inducing their apoptosis. However, resistance to ionizing radiation may develop during radiotherapy cycles, leading to an increase in the number of DNA points of control that protect cells from apoptosis. Cancer stem cells are essential for radioresistance, and due to their ability to undergo epithelial–mesenchymal transition, they modify the phenotype, bypassing the genotoxic effect of radiotherapy. It is therefore necessary to search for new methods that could improve the cytotoxic effect of cells through new mechanisms of action. Chinese medicine, with several thousand years of tradition, offers a wide range of possibilities in the search for compounds that could be used in conventional medicine. This review introduces the potential candidates that may present a radiosensitizing effect on lung cancer cells, breaking their radioresistance. Additionally, it includes candidates taken from conventional medicine—drugs commonly available in pharmacies, which may also be significant candidates.

show abstract

Metformin enhances radiosensitivity in hepatocellular carcinoma by inhibition of specificity protein 1 and epithelial-to-mesenchymal transition

Cited by 7 publications

References 34 publications

Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions

Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions

Radioprotective countermeasures for radiation injury (Review)

A Cross-Talk about Radioresistance in Lung Cancer—How to Improve Radiosensitivity According to Chinese Medicine and Medicaments That Commonly Occur in Pharmacies

Contact Info

Product

Resources

About